Parkman Healthcare Partners LLC increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 13.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 869,759 shares of the company's stock after buying an additional 106,012 shares during the quarter. Replimune Group accounts for 1.4% of Parkman Healthcare Partners LLC's portfolio, making the stock its 26th biggest holding. Parkman Healthcare Partners LLC owned approximately 1.27% of Replimune Group worth $10,533,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also modified their holdings of the company. Sterling Capital Management LLC boosted its position in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after buying an additional 1,655 shares during the period. Tower Research Capital LLC TRC boosted its stake in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd increased its position in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after acquiring an additional 8,183 shares during the period. XTX Topco Ltd bought a new stake in shares of Replimune Group in the fourth quarter valued at approximately $137,000. Finally, Freestone Grove Partners LP acquired a new position in Replimune Group in the fourth quarter valued at about $140,000. 92.53% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. BMO Capital Markets raised their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $19.43.
Read Our Latest Report on REPL
Replimune Group Stock Performance
Replimune Group stock opened at $7.41 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The company has a market capitalization of $570.68 million, a PE ratio of -2.41 and a beta of 0.68. The company has a 50 day moving average price of $9.27 and a 200-day moving average price of $11.45. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00.
Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.
Replimune Group Company Profile
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
See Also
Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
